Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.

The pathogenic bacterium Pseudomonas aeruginosa has the ability to cause severe acute and chronic infections in humans. Pseudomonas exotoxin A (PE) is the most toxic virulence factor of this bacterium. It has ADP-ribosylation activity and decisively affects the protein synthesis of the host cells. The cytotoxic pathways of PE have been elucidated, and it could be shown that PE uses several molecular strategies developed under evolutionary pressure for effective killing. Interestingly, a medical benefit from this molecule has also been ascertained in recent years and several PE-based immunotoxins have been constructed and tested in preclinical and clinical trials against different cancers. In these molecules, the enzymatic active domain of PE is specifically targeted to tumor-related antigens. This review describes the current knowledge about the cytotoxic pathways of PE. Additionally, it summarizes preclinical and clinical trials of PE-based immunotoxins and furthermore discusses current problems and answers with these agents.

[1]  W. Wels,et al.  Antitumor effect of an HER2‐specific antibody–toxin fusion protein on human prostate cancer cells , 2001, The Prostate.

[2]  C. Proud Peptide-chain elongation in eukaryotes , 1994, Molecular Biology Reports.

[3]  J. Rothman,et al.  The capacity to retrieve escaped ER proteins extends to the trans-most cisterna of the Golgi stack , 1995, The Journal of cell biology.

[4]  I. Pastan,et al.  In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma , 2004, Cancer Research.

[5]  M. Schroth,et al.  Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa. , 1974, Applied microbiology.

[6]  M. Moroni,et al.  Pseudomonas infections in patients with AIDS and AIDS‐related complex , 1992, Journal of internal medicine.

[7]  J. Chang,et al.  Expression of 14-3-3delta, cdc2 and cyclin B proteins related to exotoxin A-induced apoptosis in HeLa S3 cells. , 2007, International immunopharmacology.

[8]  L. Steinstraesser,et al.  Host defense peptides in burns. , 2004, Burns : journal of the International Society for Burn Injuries.

[9]  V. Diehl,et al.  Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. , 1998, International journal of molecular medicine.

[10]  R. Read,et al.  Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. , 1997, Biochemistry.

[11]  I. Pastan,et al.  Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Mckay,et al.  Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  I. Pastan,et al.  Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Tommassen,et al.  Secretion of Elastinolytic Enzymes and Their Propeptides by Pseudomonas aeruginosa , 1998, Journal of bacteriology.

[15]  D. Kabat,et al.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[16]  I. Pastan,et al.  Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.

[17]  N. Dang,et al.  Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies , 2007, Cancer investigation.

[18]  R. Bast,et al.  Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. , 2001, Gynecologic oncology.

[19]  Rab9 functions in transport between late endosomes and the trans Golgi network. , 1993, The EMBO journal.

[20]  U. Wetterauer,et al.  A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells , 2006, Cancer Immunology, Immunotherapy.

[21]  J. D. White,et al.  Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Pastan,et al.  Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Neefjes,et al.  Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. , 2000, Immunity.

[24]  I. Pastan,et al.  Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  James J. Vincent,et al.  Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1 , 2006, The Journal of Immunology.

[26]  M. Berger,et al.  Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors , 2003, Journal of Neuro-Oncology.

[27]  M. Bally,et al.  GSP-dependent protein secretion in gram-negative bacteria: the Xcp system of Pseudomonas aeruginosa. , 1998, FEMS microbiology reviews.

[28]  R. Kreitman,et al.  An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. , 1997, Biochemistry.

[29]  V. Malhotra,et al.  Src Regulates Golgi Structure and KDEL Receptor-dependent Retrograde Transport to the Endoplasmic Reticulum* , 2003, Journal of Biological Chemistry.

[30]  A. Omori,et al.  Molecular Cloning, Sequencing, and Expression of the Gene Encoding Alkaline Ceramidase from Pseudomonas aeruginosa , 1999, The Journal of Biological Chemistry.

[31]  G. Maschmeyer,et al.  Review of the Incidence and Prognosis of Pseudomonas aeruginosa Infections in Cancer Patients in the 1990s , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[32]  W. Wilson,et al.  Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Rappuoli,et al.  Three conserved consensus sequences identify the NAD‐binding site of ADP‐ribosylating enzymes, expressed by eukaryotes, bacteria and T‐even bacteriophages , 1996, Molecular microbiology.

[34]  R. Puri,et al.  Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor , 2005, Journal of immunotherapy.

[35]  R. Puri,et al.  Targeting interleukin-4 receptors for effective pancreatic cancer therapy. , 2002, Cancer research.

[36]  P. Friedman,et al.  BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. , 1993, Cancer research.

[37]  G. Schreiber,et al.  In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. , 1997, Blood.

[38]  E. Vitetta Immunotoxins and vascular leak syndrome. , 2000, Cancer journal.

[39]  J. Tommassen,et al.  Identification of a Chitin-Binding Protein Secreted by Pseudomonas aeruginosa , 2000, Journal of bacteriology.

[40]  P. Koehl,et al.  Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. , 2001, Journal of molecular biology.

[41]  D. Saul,et al.  A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. , 2002, Cancer research.

[42]  M. Vasil,et al.  Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. , 1986, The Journal of pediatrics.

[43]  I. Pastan,et al.  Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. , 1995, The Biochemical journal.

[44]  H. Cunliffe,et al.  Characterization of an Endoprotease (PrpL) Encoded by a PvdS-Regulated Gene in Pseudomonas aeruginosa , 2001, Infection and Immunity.

[45]  R. Puri,et al.  Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. , 2000, Cancer research.

[46]  Ø. Fodstad,et al.  Downregulation of the antiapoptotic MCL‐1 protein and apoptosis in MA‐11 breast cancer cells induced by an anti‐epidermal growth factor receptor–Pseudomonas exotoxin a immunotoxin , 2004, International journal of cancer.

[47]  G. R. Andersen,et al.  Stealth and mimicry by deadly bacterial toxins. , 2006, Trends in biochemical sciences.

[48]  I. Pastan,et al.  Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. , 1999, Human gene therapy.

[49]  J. Tommassen,et al.  Characterization of Pseudomonas aeruginosa Chitinase, a Gradually Secreted Protein , 2001, Journal of bacteriology.

[50]  E. Vitetta,et al.  Vascular leak syndrome: a side effect of immunotherapy. , 1997, Immunopharmacology.

[51]  E. Chen,et al.  Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Wels,et al.  Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors , 2007, Molecular Cancer Therapeutics.

[53]  W. Grizzle,et al.  A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  Alain Filloux,et al.  A novel type II secretion system in Pseudomonas aeruginosa , 2002, Molecular microbiology.

[55]  A. Schwan,et al.  Exotoxin A–eEF2 complex structure indicates ADP ribosylation by ribosome mimicry , 2005, Nature.

[56]  A. Martínez,et al.  Identification of an additional member of the secretin superfamily of proteins in Pseudomonas aeruginosa that is able to function in type II protein secretion , 1998, Molecular microbiology.

[57]  D. V. Von Hoff,et al.  In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. , 1993, The Journal of urology.

[58]  I. Pastan,et al.  Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli , 1987, Cell.

[59]  I. Pastan,et al.  Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A , 2001, Journal of immunotherapy.

[60]  A. Prince,et al.  Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. , 2007, Current opinion in pharmacology.

[61]  A. Plückthun,et al.  A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  I. Pastan,et al.  The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K Nakayama,et al.  Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. , 1997, The Biochemical journal.

[64]  T. Oda,et al.  Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin. , 1998, Journal of biochemistry.

[65]  R. Pepperkok,et al.  The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. , 1999, Journal of cell science.

[66]  I. Pastan,et al.  Targeted therapy of cancer with recombinant immunotoxins. , 1997, Biochimica et biophysica acta.

[67]  I. Pastan,et al.  Administration of disulfide‐stabilized Fv‐immunotoxins B1(dsFv)‐PE38 and B3(dsFv)‐PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice , 1995, International journal of cancer.

[68]  Sebastian Harder,et al.  Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas , 2005, Breast Cancer Research.

[69]  H. P. Fell,et al.  Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[70]  R. Puri,et al.  Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. , 2001, Cancer research.

[71]  H. Pelham,et al.  Toxin entry: how reversible is the secretory pathway? , 1992, Trends in cell biology.

[72]  D. Musher,et al.  Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  M. Vasil,et al.  Molecular comparison of a nonhemolytic and a hemolytic phospholipase C from Pseudomonas aeruginosa , 1990, Journal of bacteriology.

[74]  R. Puri,et al.  Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  D. Liggitt,et al.  Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  T. Kinzy,et al.  Dominant-negative mutant phenotypes and the regulation of translation elongation factor 2 levels in yeast , 2005, Nucleic acids research.

[77]  B. Azadian,et al.  Two Neutropenic Patients with Multiple Resistant Pseudomonas Aeruginosa Septicaemia Treated with Ciprofloxacin , 1987, Journal of the Royal Society of Medicine.

[78]  H. Hirschberg,et al.  Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. , 2004, Journal of neurosurgery.

[79]  K. Klimpel,et al.  Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases , 1995, Infection and immunity.

[80]  D. Saul,et al.  A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells , 2007, Leukemia.

[81]  P. Liu,et al.  Extracellular toxins of Pseudomonas aeruginosa. , 1974, The Journal of infectious diseases.

[82]  V. Diehl,et al.  An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETÁ) is a potent immunotoxin against a Hodgkin-derived cell line , 1999, British Journal of Cancer.

[83]  I. Pastan,et al.  Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin , 1996, Nature Medicine.

[84]  P. Linsley,et al.  Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. , 1997, Journal of immunology.

[85]  Y. Reiter Recombinant immunotoxins in targeted cancer cell therapy. , 2001, Advances in cancer research.

[86]  D. Strickland,et al.  The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. , 1992, The Journal of biological chemistry.

[87]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[88]  I. Pastan,et al.  Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  P. Michl,et al.  Bacteria and bacterial toxins as therapeutic agents for solid tumors. , 2004, Current cancer drug targets.

[90]  B. Groner,et al.  Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2 , 2003, Breast Cancer Research and Treatment.

[91]  I. Pastan,et al.  Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. , 1990, The Journal of biological chemistry.

[92]  I. Pastan,et al.  Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  S. Létoffé,et al.  Isolation and characterization of an extracellular haem‐binding protein from Pseudomonas aeruginosa that shares function and sequence similarities with the Serratia marcescens HasA haemophore , 1998, Molecular microbiology.

[94]  I. Pastan,et al.  Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in vitro and in vivo , 2000, Molecular medicine.

[95]  A. Filloux,et al.  The AprX protein of Pseudomonas aeruginosa: a new substrate for the Apr type I secretion system. , 2001, Gene.

[96]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[97]  G. Cornelis,et al.  Assembly and function of type III secretory systems. , 2000, Annual review of microbiology.

[98]  I. Pastan,et al.  Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma , 1994 .

[99]  I. Pastan,et al.  Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. , 1993, Journal of neurosurgery.

[100]  I. Pastan,et al.  Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. , 2000, International journal of oncology.

[101]  I. Pastan,et al.  Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). , 1991, Cancer research.

[102]  Merrill Ar,et al.  Investigation into the Catalytic Role for the Tryptophan Residues within Domain III of Pseudomonas aeruginosa Exotoxin A , 1996 .

[103]  B. Groner,et al.  Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. , 1992, Cancer research.

[104]  S. Leppla,et al.  Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases , 1994, Infection and immunity.

[105]  Russo,et al.  Phase I Clinical Study of the Recombinant Oncotoxin TP4O in Superficial Bladder Cancer , 2005 .

[106]  Ludger Johannes,et al.  Rab6 Coordinates a Novel Golgi to ER Retrograde Transport Pathway in Live Cells , 1999, The Journal of cell biology.

[107]  I. Pastan,et al.  Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[108]  A. Issekutz,et al.  Pseudomonas aeruginosa Exotoxin A Induces Human Mast Cell Apoptosis by a Caspase-8 and -3-dependent Mechanism* , 2004, Journal of Biological Chemistry.

[109]  J. Rizo,et al.  Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Murray,et al.  Internalized Pseudomonas Exotoxin A can Exploit Multiple Pathways to Reach the Endoplasmic Reticulum , 2006, Traffic.

[111]  I. Pastan,et al.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  I. Pastan,et al.  Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  Anthony Asher,et al.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma , 2003, Journal of Neuro-Oncology.

[114]  A. Gillespie,et al.  Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts. , 1999, The Journal of urology.

[115]  Wilbert Bitter,et al.  Secretins of Pseudomonas aeruginosa: large holes in the outer membrane , 2003, Archives of Microbiology.

[116]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[117]  I. Pastan,et al.  Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. , 1992, The Journal of biological chemistry.

[118]  H. Pelham,et al.  pH-dependent binding of KDEL to its receptor in vitro. , 1993, The Journal of biological chemistry.

[119]  A. R. Merrill,et al.  Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A. , 2004, The Biochemical journal.

[120]  U. Wetterauer,et al.  Anti‐PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice , 2008, The Prostate.

[121]  I. Pastan,et al.  Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. , 1989, The Journal of biological chemistry.

[122]  I. Pastan,et al.  Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[123]  M. Lohoff,et al.  Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. , 1998, Journal of immunology.

[124]  D. Kabat,et al.  Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo , 1977, Infection and immunity.

[125]  I. Pastan,et al.  IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein , 2002, British Journal of Cancer.